BT Pharma closes 2.8M-euro financing
Toulouse, France-based BT Pharma, a company developing novel immunotherapeutics for HPV-associated diseases and cancers, says that it has successfully closed a new financing round of just over 2.8 million euros ($4.0 million). The round was led by Edmond de Rothschild Investment Partners. Longstanding shareholders Fonds d'Amorcage Midi-Pyrenees managed by the team of Icso Private Equity, BrevImmo, LBP, Beaufagne, Whitehall and the management of the company also participated.
The funds will enable the company to take its lead immunotherapeutic candidate, ProCervix, through the final stages of its preclinical development and to prepare to enter into clinical trials. ProCervix primarily aims to treat women who are already infected by human papillomavirus and who therefore run the risk of developing high-grade neoplasia and/or cervical cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze